Navigation Links
Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™
Date:2/15/2011

SAN DIEGO and INGELHEIM, Germany, Feb. 15, 2011 /PRNewswire/ -- Pfenex Inc., an industry leader in protein expression through the Pfenex Expression Technology™ platform and Boehringer Ingelheim International GmbH, a leading pharmaceutical company and global leader in biopharmaceutical contract development and manufacture, announced today that they have entered into a strategic agreement. It provides Boehringer Ingelheim with non-exclusive access to the Pfenex Expression Technology. Under the terms of the multi-year agreement, Pfenex Inc. will engineer production strains and processes for Boehringer Ingelheim's proprietary molecules, and molecules from Boehringer Ingelheim's contract manufacturing customers. This collaboration provides Boehringer Ingelheim and their customers with access to an industry-leading expression platform to enable preclinical and clinical development to progress much more quickly and efficiently.

"We are very pleased to have established this agreement with Boehringer Ingelheim," said Dr Bertrand Liang, CEO of Pfenex Inc. "This partnership combines a cutting edge expression technology with the leading innovative pharmaceutical company and contract services provider, facilitating the speed and reliability with which important new drugs can be brought to patients."

"This collaboration extends our contract manufacturing service portfolio by an additional high expression system and is a further step in our strategy to offer customers leading technologies," stated Simon Sturge, Corporate SVP of the Biopharmaceuticals Division at Boehringer Ingelheim. "The Pfenex Expression Technology™ delivers excellent expression rates, and we are looking forward to realizing customer projects with this technology."

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit www.boehringer-ingelheim.com.

Today, Boehringer Ingelheim is one of the world's leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its manufacturing facilities for mammalian cell culture and microbial fermentation. Boehringer Ingelheim has brought 18 molecules to market and has  many  years  of  experience  in  multiple  molecule  classes  such  as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products.

For more information contact: bio-cmo@boehringer-ingelheim.com or www.biopharma-cmo.com


'/>"/>
SOURCE Pfenex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
2. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
3. Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
6. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
7. Boehringer Ingelheim Unveils Diabetes Pipeline
8. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
9. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
10. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
11. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... , Feb. 21, 2017 Micro Guide ... report: http://www.reportlinker.com/p04711314-summary/view-report.html Micro Guide ... in hospitals, specialty clinics and ambulatory surgery centers ... coating tip. The selection of micro guide catheter ... lesion in human body. Micro guide catheters are ...
(Date:2/21/2017)... 21, 2017  Luminex Corporation (NASDAQ: LMNX ) ... authorized the initiation of a quarterly cash dividend to its ... dividend will be payable on April 14, 2017 to shareholders ... 24, 2017. The board of directors intends ... of $0.06 to holders of its common stock, representing a ...
(Date:2/21/2017)...  /PR Newswire/ -- UBM Medica,s Eye Care Group ... of Modern Retina ( www.modernretina.com ), a ... Built upon the success of Ophthalmology Times ... innovations in the areas of retinal surgery, clinical information, ... current informational needs and filling existing educational gaps, ...
Breaking Medicine Technology:
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... coffee house-caliber protein espresso drinks, announced its products are now available for purchase ... Coffee Protein Drink Mix has become popular among health-conscious consumers who love coffee ...
(Date:2/20/2017)... ... February 21, 2017 , ... Nancy Johnston Toll ... a way to “ Getting Over the Bump in the Road ” (published by ... learned on how to cope with the ups and downs experienced by anyone going ...
(Date:2/20/2017)... Orlando, FL (PRWEB) , ... February 20, 2017 ... ... Director, beth[at]orbitahealth[dot]com, +1 (414) 213-8818 , Orbita, Inc., a leading provider of innovative ... software-as-a-service solution for increasing patient engagement and optimizing care journey management for home ...
(Date:2/20/2017)... ... 20, 2017 , ... Today, Biscom , the leader ... first IoT device from Biscom designed to deliver confidential patient information securely and ... HIMSS17 and will be conducting demonstrations at Booth #374. , ...
(Date:2/20/2017)... Houston, TX (PRWEB) , ... February 20, 2017 ... ... he is now offering a full range of emergency dental care at his ... teeth and gums. When patients experience dental emergencies, they are at risk for ...
Breaking Medicine News(10 mins):